Candida auris in 2026: Rapid Detection and IVD Trends
Candida auris, also known as Candidozyma auris, has become one of the most closely watched fungal pathogens in hospitals and long-term care facilities. It is not a typical consumer self-testing topic. Instead, it is a healthcare-associated infection-control challenge linked to drug resistance, silent colonization, and hospital outbreaks.
In 2026, Candida auris remains highly relevant for the diagnostic industry, especially in Europe and North America. The U.S. CDC reported 6,304 clinical cases in 2024, with national case counts continuing to rise year by year. In Europe, ECDC has warned that Candidozyma auris is spreading rapidly across healthcare systems, with more than 4,000 cases reported in EU/EEA countries between 2013 and 2023.
For IVD companies, this is more than a fungal disease topic. It reflects a broader market need for faster identification, better colonization screening, antimicrobial resistance preparedness, and scalable diagnostic manufacturing workflows that can support hospitals and laboratories during infection-control response.
1. What Is Candida auris?
Candida auris is an emerging yeast that can cause serious infections, especially in patients who are already critically ill or receiving complex medical care. It can infect the bloodstream, wounds, ears, and other body sites. Symptoms are often non-specific and may resemble bacterial infections, such as fever or chills.
One of the most important features of C. auris is colonization. Some patients may carry the organism on their skin without symptoms, but they can still spread it to other patients, surfaces, and medical equipment. This makes screening and early detection essential for healthcare facilities.
2. Why Candida auris Is a Growing Concern in Europe and North America
The United States has seen a continuous rise in reported C. auris clinical cases since 2016. According to CDC tracking data updated in March 2026, 6,304 clinical cases were reported in 2024. CDC also notes that some geographic areas continue to experience ongoing transmission, while C. auris has spread into new areas.
In Europe, ECDC reported that Candidozyma auris has moved from isolated cases to broader hospital transmission in several countries. Between 2013 and 2023, EU/EEA countries reported more than 4,000 cases, including a sharp increase to 1,346 cases reported by 18 countries in 2023 alone.
| Region | Recent Situation | Diagnostic Relevance |
| United States | 6,304 clinical cases reported in 2024, according to CDC 2026 tracking data. | Growing need for rapid identification, colonization screening, and infection-control testing workflows. |
| Europe | More than 4,000 cases reported in EU/EEA countries between 2013 and 2023. | Increasing pressure on hospital laboratories, surveillance systems, and outbreak preparedness. |
| Hospitals and long-term care facilities | Transmission can occur through colonized patients, contaminated surfaces, and medical equipment. | Rapid screening helps guide isolation, cleaning, contact precautions, and outbreak response. |
3. Why Rapid Detection Matters for Infection Control
Traditional culture remains important, but it may take time and can require advanced identification methods. Candida auris can also be misidentified as other Candida species if laboratory systems are not updated or validated for C. auris identification.
CDC guidance emphasizes that screening patients for C. auris colonization is a key strategy to prevent transmission and outbreaks in healthcare facilities. Skin swabs from the axilla and groin are commonly used for colonization screening, and real-time PCR is described by CDC as an accurate method that provides fast results for public health action.
4. What 2026 Literature Shows About Faster Candida auris Testing
Recent literature shows that faster C. auris detection is moving in several directions: PCR-based colonization screening, isothermal amplification, CRISPR-based detection, and lateral flow immunoassay development. These approaches are not identical, but they all reflect the same trend: hospitals need faster and more actionable results.
PCR-based screening: A 2026 study in Microbiology Spectrum evaluated the DiaSorin Simplexa C. auris Direct IVD assay using axillary/groin surveillance specimens. The study compared the assay with traditional culture and laboratory-developed tests, showing how PCR-based screening can support infection prevention protocols.
LAMP development: A 2026 PLOS One study reported a multiplex loop-mediated isothermal amplification assay for C. auris screening. The assay combined a broad Candida Pan target with a C. auris-specific target in one isothermal reaction, showing potential for active surveillance and infection-control programs.
CRISPR-based diagnostics: A 2026 Nature Biomedical Engineering article introduced digital SHERLOCK, or dSHERLOCK, for C. auris detection and resistance mutation analysis. The platform detected C. auris within 20 minutes in minimally processed swab samples and achieved sensitive quantification within 40 minutes.
Lateral flow immunoassay: In February 2026, NG Biotech and Hardy Diagnostics announced that NG-TEST® Candida auris received FDA Breakthrough Device Designation. The company describes the product as a lateral flow immunoassay developed for rapid identification of C. auris, showing that rapid test formats are also entering the fungal diagnostics discussion.
| Method | Main Application | Industry Value |
| Culture + identification | Clinical confirmation and isolate recovery | Important for confirmation, but slower than molecular or rapid workflows. |
| PCR | Colonization screening and molecular detection | Supports faster infection-control decisions and active surveillance. |
| LAMP | Isothermal amplification screening | May reduce dependence on complex thermal cycling equipment. |
| CRISPR-based diagnostics | Detection, quantification, and resistance mutation analysis | Shows potential for next-generation fungal diagnostics beyond positive or negative results. |
| Lateral flow immunoassay | Rapid identification from specific laboratory workflows | Simple format, fast readout, and strong relevance for outbreak investigation and lab support. |
5. Why This Topic Matters for the IVD Industry
Candida auris represents a larger shift in infectious disease diagnostics. Healthcare systems are paying more attention to antimicrobial resistance, hospital-acquired infections, outbreak preparedness, and rapid laboratory response. These needs create opportunities for molecular diagnostics, rapid test development, laboratory automation, and POCT-related manufacturing technologies.
For diagnostic manufacturers, the challenge is not only to design a sensitive assay. The final product also needs stable production, repeatable reagent dispensing, reliable material selection, consistent lamination and cutting, controlled assembly, and protective packaging. These manufacturing factors directly affect product consistency and batch-to-batch reliability.
| Manufacturing Area | Why It Matters |
| Reagent dispensing | Supports controlled volume, line quality, and repeatable assay performance. |
| Membrane and material processing | Affects absorption, flow rate, binding behavior, and production compatibility. |
| Lamination and cutting | Improves strip structure consistency and helps reduce process variation. |
| Assembly and packaging | Helps protect product stability, appearance, and usability in demanding healthcare environments. |
6. How Veldi Supports Rapid Test Manufacturing
Veldi provides rapid test production equipment, POCT automation equipment, selected raw materials, and customized manufacturing support for IVD projects. Our solutions cover key workflow steps such as dispensing, lamination, cutting, cassette assembly, pouching, labeling, and coding.
Equipment such as dispenser and spraying machines, lamination systems, cutters, assembly machines, and packaging systems can help manufacturers improve workflow stability. Suitable POCT raw materials are also essential for consistent absorption, flow, binding, and production compatibility.
FAQ
1. Is Candida auris dangerous to healthy people?
Most healthy people are not considered at high risk. Candida auris mainly affects patients who are already seriously ill, especially those with long healthcare stays or invasive medical devices.
2. Why is Candida auris difficult to control in hospitals?
It can colonize patients without symptoms, persist on surfaces and medical equipment, and spread between patients in healthcare settings. It is also often resistant to antifungal drugs.
3. Why is screening important if patients may not feel sick?
Colonized patients may carry Candida auris without symptoms but can still spread it. Screening helps healthcare facilities identify colonized patients and apply infection-control precautions earlier.
4. Are Candida auris rapid tests the same as home self-tests?
No. Current Candida auris testing is mainly designed for healthcare and laboratory settings. Rapid formats may support faster laboratory workflows, outbreak investigation, and infection-control decisions, but they are not general consumer self-tests.
5. Why should diagnostic manufacturers pay attention to Candida auris?
Candida auris reflects a wider demand for rapid, scalable, and accurate diagnostics for antimicrobial resistance and hospital-acquired infections. This creates opportunities for assay developers, laboratory suppliers, and automated diagnostic manufacturing solutions.
References
- Centers for Disease Control and Prevention. Tracking C. auris. Updated March 3, 2026. Read source
- Centers for Disease Control and Prevention. About C. auris. Updated February 26, 2026. Read source
- Centers for Disease Control and Prevention. Guidance for Detection of C. auris Colonization. Updated April 24, 2024. Read source
- European Centre for Disease Prevention and Control. Drug-resistant fungus Candidozyma auris confirmed to spread rapidly in European hospitals. Published September 11, 2025. Read source
- Leonard J, et al. Evaluation of a novel PCR-based assay for the detection of Candida auris colonization. Microbiology Spectrum. 2026. Read source
- Jang WS, et al. Development of a Loop-Mediated Isothermal Amplification (LAMP) for the screening of Candida auris. PLOS One. 2026. Read source
- Rolando JC, et al. Digital CRISPR-based diagnostics for quantification of Candida auris and resistance mutations. Nature Biomedical Engineering. 2026. Read source
- U.S. Food and Drug Administration. FDA Roundup: July 16, 2024. Simplexa C. auris Direct authorization. Read source
- NG Biotech and Hardy Diagnostics. FDA Breakthrough Device Designation – 2026 February 18. Read source
Conclusion
Blog Information
Leave your contact information and tell us what equipment or raw materials you are looking for. We will contact you as soon as possible to help you provide the most suitable solution.
- +86 13671664698
- inquiry@veldiautomation.com